IM Cannabis Q3 Revenue Falls 68% to C$1.65M; Going-Concern Warning Reiterated
IMCC sits 16% above its 52-week low of $0.5 on light trading volume (0.1× avg).
Summary
IM Cannabis reported Q3 2026 continuing-operations revenue of C$1.65M, down 68% year over year, a small gross loss, and a C$13.93M nine-month net loss, while repeating substantial doubt about its ability to continue as a going concern.
Key Events · Earnings and Guidance · IMCC
-
Q3 Revenue Collapses 68%
Revenue from continuing operations was C$1.65M versus C$5.08M in Q3 2025; nine-month revenue fell 43% to C$8.96M from C$15.77M.
-
Quarter Swings to Gross Loss
Q3 gross loss of C$0.04M versus C$1.58M gross profit a year earlier; nine-month gross profit fell 73% to C$1.33M.
-
Going-Concern Warning Reiterated
Management cites a C$2.99M shareholders' deficit, C$5.5M working capital deficit and C$2.4M cash, stating substantial doubt about the ability to continue as a going concern.
-
Losses Balloon on Financing Costs
Nine-month net loss was C$13.93M versus C$3.88M in 2025, driven by lower gross profit and C$4.64M of net finance expense.
Analysis · IMCC · Life Sciences
The Israeli medical cannabis business is shrinking faster than costs can be cut: revenue from continuing operations collapsed to C$1.65M in Q3 from C$5.08M a year earlier, and the quarter swung to a small gross loss. Against just C$2.4M of cash, the company now carries a C$2.99M shareholders' deficit and a C$5.5M working capital hole, and management states substantial doubt about its ability to continue as a going concern. What keeps the balance sheet afloat is serial convertible-note issuance (a US$1.2M note closed November 4, 2026) and the C$2.7M accounting gain on selling the German operations to a company controlled by the CEO. For a company this small, the going-concern language plus the revenue collapse is the story; the equity is a financing vehicle, not an operating business.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMCC was trading at $0.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $936.1K. The 52-week trading range was $0.50 to $62.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.